Tech Company Financing Transactions

Armata Pharmaceuticals Funding Round

Armata Pharmaceuticals secured a $4.7 million funding round on 5/1/2025. Investors included Congressionally Directed Medical Research Programs (CDMRP), Defense Health Agency and MTEC | Medical Technology Enterprise Consortium.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

4503 Glencoe Avenue
Marina del Rey,, CA 90292
USA

Phone

+1 (310) 665-2928

Website

www.armatapharma.com

Email Address

[email protected]

Overview

A Purposeful, Precise and Powerful Approach to Address the Global Antibiotic Resistance Crisis. Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections. Antibiotic overuse has led to the marked rise of multidrug-resistant bacteria, putting us on the verge of a post-antibiotic era in which common infections can be serious or life-threatening. Additionally, the use of broad-spectrum antibiotics is known for disrupting the ecology of the human microbiome, leading to disease.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Brian Varnum

        

Chief Medical Officer

Mina Pastagia

        

VP - Finance

Erin Butler

        

VP - Operations

Duane Morris

        

Browse more venture capital transactions:

Prev: 5/1/2025: AMPLY Discovery venture capital transaction
Next: 5/1/2025: Solda.AI venture capital transaction

Share this article

About Our VC Transactions Data

Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary